Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

View Full Paper
Ask AI
Bookmark
Share

Authors

SGStéphanie GuidezMRMarie‐Thérèse RubioMCMorgane Cheminant

Discussion

Loading...

Member takes

Overview

Observational analysis shows 50% complete response in patients with CNS involvement of mantle cell lymphoma, suggesting CAR T-cell therapy may improve outcomes.

Key Points

  • Median progression-free survival reached 10.2 months in mantle cell lymphoma patients with CNS involvement.
  • Cytokine release syndrome occurred in 75% of treated patients, predominantly grade 1 and grade 2.
  • Autologous stem cell transplantation was performed in 40% of patients prior to CAR T-cell therapy.
  • Findings indicate CAR T-cell therapy is a promising option for patients with CNS involvement.

Cite This Study

Guidez et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da1dhttps://doi.org/10.1182/blood-2025-3598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma2025
  2. 2P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025
  3. 3Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas2025
  4. 4Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  5. 5P14.05.B CAR T-CELL THERAPY DOES NOT LEAD TO MEDIUM-TERM NEUROCOGNITIVE DETERIORATION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMAS. A LOC NETWORK STUDY2025